# Effect of Mepolizumab in Severe Bilateral Nasal Polyps

> **NCT03085797** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 414 (actual)

## Conditions studied

- Nasal Polyps

## Interventions

- **DRUG:** Mepolizumab
- **DRUG:** Placebo
- **DRUG:** Mometasone furoate

## Key facts

- **NCT ID:** NCT03085797
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-25
- **Primary completion:** 2019-12-11
- **Final completion:** 2019-12-11
- **Target enrollment:** 414 (ACTUAL)
- **Last updated:** 2021-08-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03085797

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03085797, "Effect of Mepolizumab in Severe Bilateral Nasal Polyps". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03085797. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*